Orbital IgG4-related disease, which can occur in adults of any age, is characterized by IgG4-positive lymphoplasmacytic infiltrations in ocular adnexal tissues. The signs and symptoms include chronic noninflammatory lid swelling and proptosis. Patients often have a history of allergic disease and elevated serum levels of IgG4 and IgE as well as hypergammaglobulinemia. Orbital IgG4-related disease must be differentiated from idiopathic orbital inflammation and ocular adnexal marginal zone B-cell lymphoma to ensure appropriate and effective treatment. Systemic steroid therapy decreases the size of the lesions, but relapse often occurs when systemic steroid therapy is discontinued. 1. Introduction IgG4-related diseases are systemic syndromes characterized by elevated serum levels of IgG4 and IgG4-positive lymphoplasmacytic infiltrative lesions in the body. Orbital tissues are affected by IgG4-related conditions. It was first observed that Mikulicz’s disease correlated with IgG4-related disease [1] and later determined that IgG4-related disease can occur in any ocular adnexal tissues [2–5]. Here, we review the clinicopathological features, differential diagnosis, and treatments of orbital IgG4-related disease on the basis of a meta-analysis of 42 patients including 3 case series studies. 2. Clinical Presentation The median age of patients with orbital IgG4-related disease is 59 years (range: 30 to 86 years) with a 1?:?1 male-to-female ratio [3–5]. Notably, there is a 1?:?3 for bilateral lacrimal lesions similar to finding in Mikulicz’s disease [1]. Although orbital IgG4-related disease can occur in men and women of any age, many patients have a history of allergic diseases such as asthma and allergic rhinitis. The signs and symptoms of orbital IgG4-related disease are chronic lid swelling (Figure 1) and proptosis (Figure 2), but otherwise there are only mild signs, or no signs of inflammation or periocular pain. Ocular motility is restricted mildly if at all, despite the presence of one or more enlargements of the large extraocular muscles (Figure 1). There are generally no visual disturbances, although they may occur due to apical orbital lesions (Figure 2). Imaging studies show infiltrative lesions in ocular adnexal tissues such as the lacrimal glands (Figure 1) [2–5], extraocular muscles (Figure 1) [3, 4], infraorbital nerves (Figure 2) [4], optic nerve sheath [4], lacrimal sac [6], and even cavernous sinus (Figure 2) or the intracranial extension [4]. In cases of orbital IgG4-related disease, 62% have bilateral lesions, 69% have lacrimal gland
References
[1]
M. Yamamoto, H. Takahashi, S. Sugai, and K. Imai, “Clinical and pathological characteristics of Mikulicz's disease,” Autoimmunity Reviews, vol. 4, no. 4, pp. 195–200, 2005.
[2]
M. Takahira, M. Kawano, Y. Zen, H. Minato, K. Yamada, and K. Sugiyama, “IgG4-related chronic sclerosing dacryoadenitis,” Archives of Ophthalmology, vol. 125, no. 11, pp. 1575–1578, 2007.
[3]
T. Kubota, S. Moritani, M. Katayama, and H. Terasaki, “Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder,” Archives of Ophthalmology, vol. 128, no. 5, pp. 577–584, 2010.
[4]
J. A. Plaza, J. A. Garrity, A. Dogan, A. Ananthamurthy, T. E. Witzig, and D. R. Salom?o, “Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease,” Archives of Ophthalmology, vol. 129, no. 4, pp. 421–428, 2011.
[5]
Y. Sato, K. I. Ohshima, K. Ichimura et al., “Ocular adnexal IgG4-related disease has uniform clinicopathology,” Pathology International, vol. 58, no. 8, pp. 465–470, 2008.
[6]
R. Batra, H. S. Mudhar, and S. Sandramouli, “A unique case of IgG4 sclerosing dacryocystitis,” Ophthalmic Plastic Reconstractive Surgery, vol. 28, no. 3, pp. e70–e72, 2012.
[7]
F. A. Jakobiec, R. C. Stacy, and M. P. Hatton, “Clinical characterization and immunopathologic features of sclerosing dacryoadenitis and Riedel thyroiditis,” Archives of Ophthalmology, vol. 128, no. 12, pp. 1626–1628, 2010.
[8]
S. M. Patel and J. H. Szostek, “IgG4-related systemic disease in a native American man,” Internal Medicine, vol. 50, no. 8, pp. 931–934, 2011.
[9]
H. Moteki, M. Yasuo, H. Hamano, T. Uehara, and S. I. Usami, “IgG4-related chronic rhinosinusitis: a new clinical entity of nasal disease,” Acta Oto-Laryngologica, vol. 131, no. 5, pp. 518–526, 2011.
[10]
Y. Zen, T. Fujii, K. Harada et al., “Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis,” Hepatology, vol. 45, no. 6, pp. 1538–1546, 2007.
[11]
Y. Sato, K. Notohara, M. Kojima, K. Takata, Y. Masaki, and T. Yoshino, “IgG4-related disease: historical overview and pathology of hematological disorders: review Article,” Pathology International, vol. 60, no. 4, pp. 247–258, 2010.
[12]
T. Kubota, “Orbital myositised,” in Idiopathic Inflammatory Myopathies-Recent Developments, J. T. Gran, Ed., pp. 123–142, InTech, 2011, http://www.intechopen.com/books/idiopathic-inflammatory-myopathies-recent-developments/orbital-myositis.
[13]
J. A. Ferry, C. Y. Fung, L. Zukerberg et al., “Lymphoma of the ocular adnexa: a study of 353 cases,” American Journal of Surgical Pathology, vol. 31, no. 2, pp. 170–184, 2007.
[14]
T. Kubota, S. Moritani, T. Yoshino, H. Nagai, and H. Terasaki, “Ocular adnexal marginal zone B cell lymphoma infiltrated by IgG4-positive plasma cells,” Journal of Clinical Pathology, vol. 63, no. 12, pp. 1059–1065, 2010.
[15]
W. Cheuk, H. K. L. Yuen, A. C. L. Chan et al., “Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG4-related sclerosing disease,” American Journal of Surgical Pathology, vol. 32, no. 8, pp. 1159–1167, 2008.
[16]
W. R. Bijlsma, R. J. Hené, M. P. Mourits, and R. Kalmann, “Orbital mass as manifestation of Wegener's granulomatosis: an ophthalmologic diagnostic approach,” Clinical and Experimental Rheumatology, vol. 29, no. 1, supplement 64, pp. S35–S39, 2011.
[17]
M. Yamamoto, H. Takahashi, C. Suzuki et al., “Analysis of serum IgG subclasses in churg-strauss syndrome-The meaning of elevated serum levels of IgG4,” Internal Medicine, vol. 49, no. 14, pp. 1365–1370, 2010.
[18]
M. Yamamoto, H. Takahashi, M. Ohara et al., “A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease,” Modern Rheumatology, vol. 16, no. 6, pp. 335–340, 2006.
[19]
A. Khosroshahi, D. B. Bloch, V. Deshpande, and J. H. Stone, “Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1755–1762, 2010.